A Multicentre Trial with Bacampicillin (Penglobe®) in the Treatment of Respiratory Tract Infections in General Practice

Abstract

Nine hundred and eleven patients were admitted to a multicentre trial with bacampicillin (Penglobe®) in respiratory tract infections. Of these it was possible to evaluate 830 with respect to efficacy and side-effects. In most cases a dosage of 400 mg × 2 was used but in severe cases 800 mg × 2 was used. The clinical outcome was assessed as good for 79% of the patients, while 17% showed an improvement and 3% a failure. The tolerance was good with an over-all incidence of 8% side-effects, of which dyspepsia was the most common.